Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 17274
Country/Region: Botswana
Year: 2016
Main Partner: University of Maryland
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $4,214,962 Additional Pipeline Funding: $298,216

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,205,678
Care: Pediatric Care and Support (PDCS) $360,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $127,500
Treatment: Adult Treatment (HTXS) $2,161,784
Treatment: Pediatric Treatment (PDTX) $360,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,775
PMTCT_ART New on ART 2017 1,404
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 16,335
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,926
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,254
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 21
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 49
PMTCT_EID Sum of Infant Age disaggregates 2017 4,180
PMTCT_STAT By: Known positives at entry 2017 727
PMTCT_STAT By: Number of new positives identified 2017 3,673
PMTCT_STAT Number of new ANC and L&D clients 2017 16,335
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 16,335
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,400
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 7,511
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 5,198
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,254
TB_SCREENDX Screen Results: Screened Positive for TB 2017 7,511
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 1,413
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 1,145
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 109,261
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 67,099
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 178,918
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,044
TX_CURR Aggregated Age/Sex: <15 Male 2017 3,269
TX_CURR Aggregated Age/Sex: 15+ Female 2017 106,319
TX_CURR Aggregated Age/Sex: 15+ Male 2017 65,286
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 178,918
TX_CURR Sum of Aggregated Age/Sex <15 2017 7,313
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 171,605
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 178,918
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,450
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,186
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 20,021
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 12,293
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 34,950
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 34,950
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 143,136
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 132,181
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,073
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 879
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 83,030
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 50,996
TX_PVLS Numerator: Indication: Routine 2017 132,181
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,122
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 928
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 84,647
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 53,987
TX_PVLS_den Denominator: Indication: Routine 2017 143,136
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 143
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 116
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11,073
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 156
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,713
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 96
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 18,040
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 256
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 21,200
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 301
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 172
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 134
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12,943
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 184
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,944
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 113